BioMarin Pharmaceutical Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by BioMarin Pharmaceutical Inc. on December 17, 2025, covering events reported on December 11, 2025. The filing addresses Item 5.02 regarding the appointment of a new executive officer.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation and appointment details.
Material Changes
The primary material change is the appointment of Rashmi Ramchandani as Vice President, Chief Accounting Officer, effective January 19, 2026. In this role, she will assume the position of principal accounting officer from Brian Mueller, who will continue as Executive Vice President and Chief Financial Officer.
Management Commentary and Compensation Details
Ms. Ramchandani's compensation package includes the following components:
- Base Salary: $460,000 annually.
- Sign-on Bonus: $400,000, subject to repayment if employment terminates within the first two years (excluding job elimination, death, or disability).
- Annual Bonus: Eligible for the standard employee bonus program starting in 2026, with a target payout of 45% of base salary.
- Restricted Stock Units (RSUs):
- $1,050,000 grant vesting 25% annually over four years.
- $400,000 grant vesting 100% on the first anniversary.
- Stock Options: $450,000 grant with 25% vesting on the first anniversary and monthly vesting thereafter.
Ms. Ramchandani brings prior experience from Gilead Sciences, Strava, The Clorox Company, McKesson Corporation, and Deloitte.
Investor Verification Checklist
- Confirm the effective start date of January 19, 2026, for the new Chief Accounting Officer.
- Verify the total equity value granted ($1,850,000 in RSUs and $450,000 in Options) against current stock price fluctuations.
- Review the repayment clause for the $400,000 sign-on bonus regarding early termination conditions.
- Monitor future filings for the actual grant date and share count calculations based on the 30-day trailing average price.